Takeda Pharmaceutical (TKPHF) Gains from Investment Securities (2018 - 2026)

Takeda Pharmaceutical's Gains from Investment Securities history runs 9 years deep, the most recent figure standing at -$411.1 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 24.85% year-over-year to -$411.1 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 6.59% YoY), while the FY2026 annual figure was -$1.2 billion, down 7.02% from the prior year.
• Gains from Investment Securities was -$411.1 million for Q1 2026 at Takeda Pharmaceutical, down from -$156.2 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of -$156.2 million in Q4 2025 to a low of -$655.2 million in Q3 2022.
• Historically, Gains from Investment Securities has averaged -$331.9 million across 5 years, with a median of -$340.0 million in 2023.
• Biggest YoY gain for Gains from Investment Securities was 45.6% in 2023; the steepest drop was 111.5% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at -$410.1 million in 2022, then increased by 17.08% to -$340.0 million in 2023, then surged by 39.51% to -$205.7 million in 2024, then gained by 24.06% to -$156.2 million in 2025, then slumped by 163.23% to -$411.1 million in 2026.
• The last three Gains from Investment Securities figures came in at -$411.1 million (Q1 2026), -$156.2 million (Q4 2025), and -$374.9 million (Q3 2025), per Business Quant data.